Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials

Xu, Ping; Li, Lan; Yu, Chaohui; Li, Youming

doi:10.5152/tjg.2016.15535

Cited by 4 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From decompensated cirrhosis To hepatocellular carcinoma All ages 96 3.5 7.1 5.1-11.5 [22] To liver transplantation All ages 325 2.0 8.7 6.6-11.4 [29] To death All ages 152 2.0-10.0 15.0 9.9-20.0 [22] From hepatocellular carcinoma To liver transplantation All ages 325 2.0 8.7 6.6-11.4 [29] To death All ages 8,424 8.9-37.0 26.6 8.1-54.5 [22] From liver transplantation…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Dai

Wong

Xie

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Dai

Wong

Xie

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…Hence, an epidemiological survey of the natural history of PBC patients in the absence of treatment might contribute to a greater understanding of the natural history of patients with UDCA-resistant PBC and in developing criteria for estimating UDCA response. A recent study demonstrated greatly reduced serum levels of ALP and very slight fluctuations in the other biochemical parameters of PBC patients treated with placebo at the 2 year follow-up period[165]. There was histological development in 39.4% of patients treated with placebo and a mild worsening of histological grade after 2 years of research[165].…”

Section: Natural History Of Pbcmentioning

confidence: 99%

“…A recent study demonstrated greatly reduced serum levels of ALP and very slight fluctuations in the other biochemical parameters of PBC patients treated with placebo at the 2 year follow-up period[165]. There was histological development in 39.4% of patients treated with placebo and a mild worsening of histological grade after 2 years of research[165]. In the meantime, histological progression was observed in 39.4% of the placebo-treated patients, with a moderate deterioration in histological scores noted after 2 years.…”

Section: Natural History Of Pbcmentioning

confidence: 99%

“…In the meantime, histological progression was observed in 39.4% of the placebo-treated patients, with a moderate deterioration in histological scores noted after 2 years. Furthermore, the pooled 2 year rates of death, transplant, and progression of varicosities were 11.4%, 8.7% and 10.6%, respectively, in patients treated with placebo[165]. The natural history of PBC patients with AIH characteristics significantly differs from those without AIH characteristics[160].…”

Section: Natural History Of Pbcmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Huang¹

2016

WJH

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is an infrequent progressive intrahepatic cholestatic autoimmune illness that can evolve into hepatic fibrosis, hepatic cirrhosis, hepatic failure, and, in some cases, hepatocellular carcinoma. The disease itself is characterized by T-lymphocyte-mediated chronic non-suppurative destructive cholangitis and elevated serum levels of extremely specific anti-mitochondrial autoantibodies (AMAs). In this article, we will not only review epidemiology, risk factors, natural history, predictive scores, radiologic approaches (e.g., acoustic radiation force impulse imaging, vibration controlled transient elastography, and magnetic resonance elastography), clinical features, serological characteristics covering biochemical markers, immunoglobulins, infections markers, biomarkers, predictive fibrosis marker, specific antibodies (including AMAs such as AMA-M2), anti-nuclear autoantibodies [such as anti-multiple nuclear dot autoantibodies (anti-sp100, PML, NDP52, anti-sp140), anti-rim-like/membranous anti-nuclear autoantibodies (anti-gp210, anti-p62), anti-centromere autoantibodies, and some of the novel autoantibodies], histopathological characteristics of PBC, diagnostic advances, and anti-diastole of PBC. Furthermore, this review emphasizes the recent advances in research of PBC in terms of therapies, including ursodeoxycholic acid, budesonide, methotrexate, obeticholic acid, cyclosporine A, fibrates such as bezafibrate and fenofibrate, rituximab, mesenchymal stem cells transplant, and hepatic transplant. Currently, hepatic transplant remains the only optimal choice with acknowledged treatment efficiency for end-stage PBC patients.

show abstract

“…Medicações como a lactulose, o aspartato de ornitina (Hepa-Merz® ) e alguns antibióticos (principalmente a neomicina) são utilizados corriqueiramente para manejar a encefalopatia hepática (Elwir;Rahimi, 2017). O ácido ursodesoxicólico (ursacol®), em geral, é utilizado no tratamento da cirrose biliar primária, para a dissolução dos cálculos biliares formados por colesterol em pacientes que apresentam colelitíase (Xu et al, 2016).…”

Section: Critérios De Exclusãounclassified

Sangramento pós-exodôntico em pacientes em fila de transplante hepático: análise retrospectiva

Medina¹

View full text Add to dashboard Cite

Hepatic cirrhosis is the result of all long-term chronic diseases, which can compromise the liver, and is characterised by hepatic insufficiency (HI) and portal hypertension (PH). The coagulopathies seen in cirrhotic patients depend on several mechanisms involving both HI and PH, which impairs the routine physiological functions of the liver, such as synthesis of all coagulation factors, except the von Willebrand factor. All dental studies published until today could not associate the two tests commonly used prior to tooth extraction in these patients, namely, INR and platelets count, for presence of haemorrhagic events. The objective of this work was to assess the presence of intra-and post-operative bleeding in cirrhotic patients undergoing tooth extraction and to verify whether there exists an association between laboratory (i.e. platelets, haemoglobins, INR, TTPa, urea, creatinine) and clinical parameters (i.e. cirrhosis complications, disease stage, MELD score, type of tooth extraction, surgery time, number of teeth extracted). This is a cross-sectional, retrospective, observational study of cirrhotic patients who were on the liver transplant waiting list at the Healthcare Centre for Special Patients (CAPE) of the University of São Paulo Faculty of Dentistry (FOUSP). Data were obtained from the medical records of 224 patients and the Epi Info software was used to generate a database. A total of 190 visits were performed for 99 patients, resulting in 333 teeth extracted. The majority of the patients were male (75.44%) with mean age of 51.27 years old and elementary education level (23.56%). The greatest cause was hepatitis C (40.18%) and the most common cirrhosis complications were collateral circulation (66.80%), hepatic encephalopathy (56.30%) and ascite (64.20%). Plateletopenia (95.80%) was identified in 190 blood counts, anaemia (67.90%) in 129, and white blood cell changes in 110 (57.80%). The mean scores for INR was 1.45 (minimum 1.03 and maximum 2.71) and for platelets was 76,380 (minimum 16,000 and maximum 216,000). Only 12 patients presented haemorrhagic events during surgery and 12 after it. The only positive association was found between platelet counts and intra-operative haemorrhagic events (P = 0.26; Mann Whitney's test, confirmed with linear regression analysis). All the bleeding events were controlled with local measures. Cirrhotic patients who were on the liver transplant waiting list had a few bleeding events, all with little severity. Intra-operative haemorrhagic events are more likely to occur when the platelet count is low, but bleeding can be handled with simple local measures. Post-operative haemorrhagic events could not be associated with any variable, but no patient needed blood transfusion as the clinical picture improved spontaneously.

show abstract

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials

Cited by 4 publications

References 30 publications

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Sangramento pós-exodôntico em pacientes em fila de transplante hepático: análise retrospectiva

Contact Info

Product

Resources

About